SCHEMBL6979263

SCHEMBL6979263

CCOC(=O)c1cn2c3ccc(Br)cc3c3cc(OC)cc(c1=O)c32

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.60
GABRA1 P14867 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRA3 P34903 1/20 0.48
GABRB2 P47870 1/20 0.48
ELANE P08246 3/20 0.45
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 2/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KMT2A Q03164 2/20 0.40
ATM Q13315 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6976246 0.86 ALDH1A1 (0.50) LMNAALDH1A1HPGDKDM4ETSHR
SCHEMBL6975262 0.82 PIK3R1 (0.38) LMNAGABRA1GABRB1GABRA3GABRB2
SCHEMBL6983087 0.77 LMNA (0.44) LMNAGABRA1GABRB1GABRA3GABRB2
SCHEMBL17246317 0.76 LMNA (0.71) LMNAALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL6979851 0.76 LMNA (0.41) LMNAGABRA1GABRB1GABRA3GABRB2
SCHEMBL3819905 0.75 LMNA (1.00) LMNAGABRA1GABRB1GABRA3GABRB2
SCHEMBL6975925 0.74 PTGDR2 (0.41) LMNAALDH1A1HPGDKDM4EHSD17B10
SCHEMBL6976583 0.73 LMNA (0.40) LMNAGABRA1GABRB1GABRA3GABRB2
SCHEMBL6978385 0.73 CYP19A1 (0.37) LMNAGABRA1GABRB1GABRA3GABRB2
SCHEMBL15167352 0.72 LMNA (0.62) LMNAGABRA1GABRB1GABRA3GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0985671-B1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARM CO LTD (JP) 2003-04-02 EP disclosed
US-6197768-B1 THERAPY, PREVENTION ISCHEMIC HEART DISEASE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2001-03-06 US disclosed
EP-0985671-A1 PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-03-15 EP disclosed
US-6018046-A SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-01-25 US disclosed